A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2014

At a glance

  • Drugs Sorafenib (Primary) ; Tivantinib (Primary)
  • Indications Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors ArQule
  • Most Recent Events

    • 23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2013 Planned end date changed from 1 Oct 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 14 Mar 2013 Phase 1b data was presented at the ASCO Annual Meeting, according to an ArQule media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top